Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7444)
All Articles published online
|
Publishing Process of This Article
|
Apr 7, 2020 (publication date) through Apr 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Abou Jokh Casas E, Pubul Núñez V, Anido-Herranz U, del Carmen Mallón Araujo M, del Carmen Pombo Pasín M, Garrido Pumar M, Cabezas Agrícola JM, Cameselle-Teijeiro JM, Hilal A, Ruibal Morell Á. Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors. World J Gastroenterol 2020; 26(13): 1513-1524 [PMID: 32308351 DOI: 10.3748/wjg.v26.i13.1513] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v26/i13/1513.htm |
| Number | Citing Articles |
| 1 |
Alejandro Mejia, Elaina Vivian, Christiana Nwogu, Jimmy Shah, Raquel Longoria, Allison Vo, Islam Shahin, Jonathan Verma, Alexandru Bageac. Peptide receptor radionuclide therapy implementation and results in a predominantly gastrointestinal neuroendocrine tumor population. Medicine 2022; 101(9): e28970 doi: 10.1097/MD.0000000000028970
|
| 2 |
Julien Dubois, Guillaume Tosato, Philippe Garrigue, David Taieb, Benjamin Guillet, Vincent Nail. Short-Term Biological Toxicity Prediction of [177Lu]Lutetium-Oxodotreotide: An Original Retrospective Analysis. Cancer Biotherapy and Radiopharmaceuticals 2024; doi: 10.1089/cbr.2023.0195
|
| 3 |
Amit Nautiyal, Sofia Michopoulou, Matt Guy. Dosimetry in Lu-177-DOTATATE peptide receptor radionuclide therapy: a systematic review. Clinical and Translational Imaging 2023; 12(2): 157 doi: 10.1007/s40336-023-00589-x
|
| 4 |
Samina Roohi, Shakera Khatoon Rizvi, Syed Ali Raza Naqvi. 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Indigenously Developed Freeze Dried Cold Kit and Biological Response in In-Vitro and In-Vivo Models. Dose-Response 2021; 19(1): 155932582199014 doi: 10.1177/1559325821990147
|
| 5 |
|
| 6 |
Shaunak Navalkissoor, Christos Toumpanakis, Martyn Caplin, Gopinath Gnanasegaran. Treatment of neuroendocrine tumours with 177Lu‐peptide receptor radionuclide therapy: Challenging clinical scenarios and their management. Journal of Neuroendocrinology 2022; 34(4) doi: 10.1111/jne.13088
|
| 7 |
Esmail Jafari, Abdul Latif Amini, Hojjat Ahmadzadehfar, Dara Bagheri, Majid Assadi. Cardiotoxicity and cardiac monitoring following the use of radiotheranostics agents including 177Lu-PSMA for prostate cancer and 177Lu-DOTATATE for neuroendocrine tumors. Nuklearmedizin 2021; 60(02): 99 doi: 10.1055/a-1332-8230
|
| 8 |
Beatriz Arruda Matheos de Lima, Rinaldo Gonçalves da Silva, Cibele Carroll, Bruno Vilhena, Carolina Perez, Renata Felix, Michel Carneiro, Luiz Machado Neto, Fernanda Vaisman, Rossana Corbo, Priscilla Brunelli Pujatti, Daniel Bulzico. Neutrophil to lymphocyte ratio as a prognosis biomarker of PRRT in NET patients. Endocrine 2022; 78(1): 177 doi: 10.1007/s12020-022-03133-5
|
| 9 |
E. Abou-Jokh Casas, N. Martínez-Lago, M.C. Mallón Araujo, J.M. Cabezas Agrícola, Z. Nogareda Seoane, A. Cousillas Castiñeira, A. Ruibal Morell, V. Pubul Núñez. Role of systemic inflammatory factors in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with peptide receptor radionuclide therapy (PRRT): From biology to theragnosis. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2023; 42(3): 156 doi: 10.1016/j.remnie.2023.02.006
|
| 10 |
E. Abou-Jokh Casas, N. Martínez-Lago, M.C. Mallón Araujo, J.M. Cabezas Agrícola, Z. Nogareda Seoane, A. Cousillas Castiñeira, A. Ruibal Morell, V. Pubul Núñez. Papel de los factores inflamatorios sistémicos en los tumores neuroendocrinos gastroenteropancreáticos (TNE-GEP) tratados con péptidos marcados con radionúclidos (PRRT): de la biología a la teragnosis. Revista Española de Medicina Nuclear e Imagen Molecular 2023; 42(3): 156 doi: 10.1016/j.remn.2022.07.003
|
| 11 |
Layla Al-mansoori, Philip Elsinga, Sayed K. Goda. Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy. Biomedicine & Pharmacotherapy 2021; 144: 112260 doi: 10.1016/j.biopha.2021.112260
|
| 12 |
Noémie S. Minczeles, Wouter W. de Herder, Richard A. Feelders, Frederik A. Verburg, Johannes Hofland, Tessa Brabander. Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with177Lu-DOTATATE in Neuroendocrine Tumor Patients. Journal of Nuclear Medicine 2023; 64(1): 40 doi: 10.2967/jnumed.122.263856
|
| 13 |
Fatemeh Ebrahimi, Seyed Jalal Hosseinimehr. Homomultimer Strategy for Improvement of Radiolabeled Peptides
and Antibody Fragments in Tumor Targeting. Current Medicinal Chemistry 2022; 29(29): 4923 doi: 10.2174/0929867329666220420131836
|
| 14 |
Michael R. Dyer, Zhenghan Jing, Kathleen Duncan, Jacqueline Godbe, Monica Shokeen. Advancements in the development of radiopharmaceuticals for nuclear medicine applications in the treatment of bone metastases. Nuclear Medicine and Biology 2024; : 108879 doi: 10.1016/j.nucmedbio.2024.108879
|
| 15 |
Dimitrios Papantoniou, Katarzyna Fröss‐Baron, Ulrike Garske‐Román, Anders Sundin, Espen Thiis‐Evensen, Malin Grönberg, Staffan Welin, Eva Tiensuu Janson. Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients. Journal of Neuroendocrinology 2024; doi: 10.1111/jne.13379
|
| 16 |
Mina M. Swiha, Duncan E. K. Sutherland, Golmehr Sistani, Alireza Khatami, Rami M. Abazid, Amol Mujoomdar, Daniele P. Wiseman, Jonathan G. Romsa, Robert H. Reid, David T. Laidley. Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS). Journal of Cancer Research and Clinical Oncology 2022; 148(1): 225 doi: 10.1007/s00432-021-03672-w
|
| 17 |
Rosaria M. Ruggeri, Irene Aini, Stefano Gay, Erika Maria Grossrubatscher, Camilla Mancini, Maria Grazia Tarsitano, Virginia Zamponi, Andrea M. Isidori, Annamaria Colao, Antongiulio Faggiano. Efficacy and tolerability of somatostatin analogues according to gender in patients with neuroendocrine tumors. Reviews in Endocrine and Metabolic Disorders 2024; 25(2): 383 doi: 10.1007/s11154-023-09858-6
|
| 18 |
Caitlin Hodge, Bridget N. Fahy. Neuroendocrine Tumors. 2021; : 293 doi: 10.1007/978-3-030-62241-1_19
|
| 19 |
Mohammadreza Kalantarhormozi, Samaneh Hassanzadeh, Seyed Javad Rekabpour, Mohammad Reza Ravanbod, Esmail Jafari, AbdulLatif Amini, Habibollah Dadgar, Mehdi Mahmoudpour, Iraj Nabipour, Narges Jokar, Majid Assadi. Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment. World Journal of Nuclear Medicine 2022; 21(03): 215 doi: 10.1055/s-0042-1755412
|